Sugi Predict

Sugi Predict / Targets / IKBKE

IKBKE

Inhibitor of nuclear factor kappa-B kinase subunit epsilon · Q14164 · IKBKE on Sugi Atlas →

50,228 patent compounds predicted against IKBKE, 31,398 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Amlexanox Amlexanox (SCHEMBL29642) 1.00 12/20
SCHEMBL98881 SCHEMBL98881 0.57 3/20
SCHEMBL100736 SCHEMBL100736 0.50 3/20
SCHEMBL101518 SCHEMBL101518 0.45 3/20
SCHEMBL99210 SCHEMBL99210 0.43 3/20
SCHEMBL101240 SCHEMBL101240 0.41 3/20
Crizotinib Crizotinib (SCHEMBL93829) 1.00 2/20
Crizotinib Crizotinib (SCHEMBL94020) 1.00 2/20
Ruxolitinib Ruxolitinib (SCHEMBL99225) 1.00 2/20
Ruxolitinib Ruxolitinib (SCHEMBL101279) 1.00 2/20
SCHEMBL99245 SCHEMBL99245 0.98 2/20
SCHEMBL99371 SCHEMBL99371 0.98 2/20
SCHEMBL103135 SCHEMBL103135 0.98 2/20
SCHEMBL98692 SCHEMBL98692 0.92 2/20
Ruxolitinib Ruxolitinib (SCHEMBL99771) 0.84 2/20
Ruxolitinib Ruxolitinib (SCHEMBL100078) 0.84 2/20
SCHEMBL143765 SCHEMBL143765 0.82 2/20
SCHEMBL101345 SCHEMBL101345 0.82 2/20
SCHEMBL100845 SCHEMBL100845 0.80 2/20
SCHEMBL98773 SCHEMBL98773 0.77 2/20

Clinical trials — most relevant to IKBKE by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease PHASE4COMPLETED
Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk PHASE2/PHASE3COMPLETED
Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation PHASE2/PHASE3COMPLETED
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room PHASE2/PHASE3COMPLETED
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients PHASE1/PHASE2COMPLETED
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma PHASE2COMPLETED
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis PHASE2RECRUITING
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation PHASE2ACTIVE_NOT_RECRUITING
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients PHASE2COMPLETED
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors PHASE2COMPLETED
9-ING-41 in Patients With Advanced Cancers PHASE2ACTIVE_NOT_RECRUITING
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma PHASE2WITHDRAWN
PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma PHASE2COMPLETED
Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma PHASE2COMPLETED
Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma PHASE2UNKNOWN
Impact of Colchicine and Low-dose Naltrexone on COVID-19 PHASE2COMPLETED
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma PHASE1COMPLETED
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma PHASE1COMPLETED
Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma PHASE1COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients PHASE1COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
IKBKB Gene Polymorphism (Single Nucleotide Polymorphism) (SNP) in Psoriatic and Psoriatic Arthritis Patients nanCOMPLETED
Novel Biomarkers in Inflammatory Bowel Disease nanCOMPLETED
The Pathophysiology of Bortezomib Induced Peripheral Neuropathy nanUNKNOWN
MicroRNAs and Cytokines in Peri-Implantitis Tissue nanUNKNOWN
Early Regenerative Intervention for Post-Traumatic Osteoarthritis nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a IKBKE binder may also engage these)

ProteinNameSimilarity
Q9R0T8 — 0.998 Q9R0T8 →
Q9WUN2 — 0.985 Q9WUN2 →
MAP4K2 Mitogen-activated protein kinase kinase kinase kinase 2 0.983 landscape →
TBK1 Serine/threonine-protein kinase TBK1 0.982 landscape →
P70218 — 0.977 P70218 →
Q61161 — 0.976 Q61161 →
Q3UFQ8 — 0.975 Q3UFQ8 →
ABHD16A Phosphatidylserine lipase ABHD16A 0.975 landscape →
Q6ZT62 — 0.974 Q6ZT62 →
Q9ESJ4 — 0.974 Q9ESJ4 →
Q6V7V2 — 0.974 Q6V7V2 →
Q13474 — 0.973 Q13474 →
P27040 — 0.973 P27040 →
Q70J99 — 0.973 Q70J99 →
Q99LG4 — 0.973 Q99LG4 →
Q09M05 — 0.972 Q09M05 →
Q5XHY1 — 0.972 Q5XHY1 →
B2RUP2 — 0.972 B2RUP2 →
MAP4K1 Mitogen-activated protein kinase kinase kinase kinase 1 0.972 landscape →
P70268 — 0.972 P70268 →
Q9NZQ3 — 0.972 Q9NZQ3 →
O94810 — 0.972 O94810 →
Q8C6B2 — 0.972 Q8C6B2 →
Q6DFJ6 — 0.972 Q6DFJ6 →
Q5R6S0 — 0.972 Q5R6S0 →
Q8ND23 — 0.971 Q8ND23 →
Q05AA6 — 0.971 Q05AA6 →
Q96MI9 — 0.971 Q96MI9 →
Q6MG55 — 0.971 Q6MG55 →
Q3ZBT2 — 0.971 Q3ZBT2 →